Under this new framework, regulators may be able to approve the treatment even when large patient populations don’t exist, if researchers can clearly show:
- How a disease works at the genetic, cellular, or molecular level;
- How a treatment addresses that mechanism, and
- Improvements that would not have been seen in patients without treatment.
This shift towards evaluating potential therapies based on how well they address specific mechanisms could speed up the development of rare disease treatments. It also means that it’s more important than ever to make sure patients and healthcare providers have a clear understanding of the science behind the disease and treatment so that they can make confident, informed decisions about their care.
Our other ideas worth exploring
Bedside Manners: How a dermatologist approaches patient education
An interview with Dr. Bianca Muylaert, a board-certified dermatologist in Canada, the US, and Brazil, about how she approaches patient education.
Building patient openness to cell and gene therapies
How to build patient openness to one-time cell and gene therapies by mirroring their expectations and lived experience.
Return of trial data to patients
A co-creative approach to returning trial data to patients builds stakeholder alignment, organizational efficiencies, and better output for patients.



